Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQF3250 in Overweight/Obese Participants
NCT07798284Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing TQF3250 capsules with TQF3250 Placebo (2 arms). Primary endpoints: Adverse Events at 14 weeks and Abnormal clinical examination findings at 14 weeks. Started Sep 2026; status: recruiting.
02
Drugs
TQF3250
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07798284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07798284.